Elicera Therapeutics says CARMA phase I data show 91% response rate for ELC-301 in relapsed B-cell lymphoma

• Elicera Therapeutics treated the final patient in the Phase I portion of the CARMA study of ELC-301 in relapsed or hard-to-treat B-cell lymphoma.
• Interim results have already been presented in this update, based on patients assessed at the one-month follow-up.
• The update showed broad disease control with most patients achieving a tumor response, including several reaching no detectable active disease.
• No dose-limiting safety issues have been observed to date, though the independent safety committee has not yet reviewed the final dose cohort.
• The committee’s upcoming review will set the recommended Phase II dose, enabling enrollment to continue into the Phase IIa expansion stage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202608110654BITN____UKPR__SV_20260811-BIT-6352-0) on August 11, 2026, and is solely responsible for the information contained therein.